‘Nonserious’ side effects may lead to antiplatelet discontinuation

Most adverse events that lead patients to discontinue antiplatelet drugs are not rated as serious by clinical trial criteria, shows analysis of the PEGASUS-TIMI 54 trial.
Source: MedWire News - Category: Consumer Health News Tags: Cardiology Source Type: news